inVentiv Health Clinical Launches Physician Network For Late-Stage Research

PRINCETON, N.J., Sept. 24, 2013 /PRNewswire/ -- inVentiv Health Clinical, a leading global supplier of drug development services, today announced the launch of an innovative, web-based network to efficiently connect physicians interested in participating in late-stage research to appropriate clinical trials.

The inVentiv Physician Network (inVentivDocNet.com), a crowdsourcing tool, promises to help research sponsors accelerate study enrollment. It is part of inVentiv Health's broad strategic investment in innovation to speed clinical trials.

"We believe physicians will find this a valuable new channel for accessing 'real-world' research opportunities," said Jeff Trotter, inVentiv Health Clinical Executive Vice President – Late Stage. "The inVentiv Physician Network welcomes virtually any clinician who seeks to participate in observational research, including patient registries, safety surveillance programs, postapproval safety studies, and other noninterventional and quality-of-life studies."

By joining the network, physicians can find easy-to-manage research opportunities involving approved products used in everyday practice. Sponsors can access the busiest and most relevant practicing physicians for their studies, accelerating both site and patient enrollment. Together, physicians and sponsors can generate real-world information that is critically important in establishing the value of medical treatments and procedures.

The inVentiv Physician Network complements inVentiv's other innovations in clinical trial recruitment. inVentiv Clinical Trial Recruitment Services (iCTRS) uses behavioral research, proprietary data, and cutting-edge technology to improve feasibility, enrollment, and patient recruitment. Mytrus Inc., in which inVentiv has acquired an equity stake, has pioneered electronic informed consent to improve trial efficiency and patient retention.

"With the inVentiv Physician Network we bring more and more physicians the opportunity to contribute vital new data to the medical community by participating in important new studies that capture real-world patient experiences and clinical outcomes," Trotter said.

inVentiv aims to enroll tens of thousands of physicians in the year ahead through an online promotional campaign aimed at practitioners in virtually all therapeutic areas. The network makes it convenient for physicians to stay abreast of late-stage research and to discover studies that suit their patients and practices. All visitors to the Physician Network website are able to view a current list of studies available for participation. Once a member, physicians may select one or more studies, and connect with the inVentiv Health Clinical team to qualify for participation. For more information and to join the inVentiv Physicians Network visit: inVentivDocNet.com

About inVentiv Health Clinical   
inVentiv Health Clinical is a leading provider of global drug development services to pharmaceutical, biotechnology, generic drug, and medical device companies, offering therapeutically specialized capabilities for Phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. With 7,000 passionate employees operating in 70 countries, inVentiv Health Clinical works to accelerate high quality drug development programs of all sizes around the world. http://www.inventivhealthclinical.com

About inVentiv Health   
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv's 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit http://www.inventivhealth.com

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties;  the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

SOURCE inVentiv Health Clinical